Apellis Pharmaceuticals
Biopharma making SYFOVRE and EMPAVELI, complement inhibitor drugs for eye and kidney disease, now owned by Biogen.
On the record
Checkpoint: Biogen Q2 2026 earnings guidance on Apellis integration and retained function scope
The call
Apellis's drugs are selling well and beating early rivals, but its future now runs through whatever Biogen decides to do with the unit it just bought.
Apellis Pharmaceuticals makes complement-inhibitor drugs (SYFOVRE and EMPAVELI) that treat rare eye and kidney diseases. The drugs are hard to copy because Apellis was first to market with FDA approval, has strong trial data, and doctors who specialize in these diseases trust and prescribe them. However, Biogen bought Apellis in May 2026, which removed the company's independent status and created uncertainty about whether Biogen will keep investing in it or simply milk profits. The one thing that will clarify everything is Biogen's earnings announcement in late July 2026, when the company will signal whether it views Apellis as a growth business worth protecting or a cash cow to be squeezed.
Why
01
AI pressure: None apparent. AI drug discovery tools speed up rivals' pipelines but don't directly threaten drugs already approved and prescribed. Could AI do the core job? Unlikely.
02
Bigger players: Astellas (Izervay), Novartis (Fabhalta), AstraZeneca/Alexion (Soliris, Ultomiris). Astellas sells a competing geographic atrophy drug and Novartis and AstraZeneca sell rival complement inhibitors in adjacent diseases. Could a giant copy it? Probably.
03
What protects it. FDA-approved first-in-class drugs with completed Phase 3 data and retina specialists already writing prescriptions for SYFOVRE.
What would change this call
Biogen's Q2 2026 earnings call (late July 2026) on Apellis integration plans. Shows whether Apellis is treated as a growth engine or a cost-cutting target.
FDA decision on SYFOVRE's prefilled-syringe submission in 1H2026. Shows whether Apellis can ease dosing friction to defend against Izervay.
Quarterly GA market-share tracking of SYFOVRE vs Astellas' Izervay through 2026. Shows whether Izervay keeps eroding SYFOVRE's lead in geographic atrophy.
FDA decision on SYFOVRE's prefilled-syringe submission in 1H2026. Shows whether Apellis can ease dosing friction to defend against Izervay.
Quarterly GA market-share tracking of SYFOVRE vs Astellas' Izervay through 2026. Shows whether Izervay keeps eroding SYFOVRE's lead in geographic atrophy.
Key numbers
- SYFOVRE holds about 60% of US GA market share
- Q1 2026 revenue $268.3M, up 61% year over year
- Biogen deal closed at $41.00 per share plus CVR
Named risks
- Post-acquisition integration could deprioritize or restructure Apellis as a Biogen unit.
- Active securities fraud class action over SYFOVRE trial disclosures as of July 2026.
- Product-liability suits over SYFOVRE-linked retinal vasculitis and vision loss.
- $94M convertible debt maturity due September 2026.
- Market share erosion in geographic atrophy from Astellas's Izervay.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Astellas Pharma (Izervay) | gaining on | 2024-11-12 meta-analysis suggests Izervay may beat pegcetacoplan on some efficacy/safety measures |
| Novartis (Fabhalta) | contesting | Fabhalta FDA-approved for PNH Dec 2023, competing directly with EMPAVELI |
| AstraZeneca/Alexion (Soliris, Ultomiris) | contesting | Established complement inhibitors in PNH market EMPAVELI targets |
| Biogen (as new parent) | contesting | Absorbed Apellis May 14, 2026 into its immunology/nephrology portfolio |
Questions people ask
- Is Apellis Pharmaceuticals still a public company?
- No. Biogen completed its acquisition of Apellis on May 14, 2026, paying $41.00 per share cash plus a contingent value right; Apellis shares were delisted from Nasdaq and it is now a wholly owned Biogen subsidiary.
- Is Apellis Pharmaceuticals profitable?
- Apellis swung to net income of $18.7 million in Q1 2026, versus a $92.2 million net loss a year earlier, on revenue of $268.3 million (up 61% year over year), per its May 7, 2026 earnings report.
- Who owns Apellis Pharmaceuticals now?
- Biogen Inc. owns Apellis outright as of May 14, 2026, after acquiring all outstanding shares for $41.00 cash plus a CVR worth up to $4/share tied to future SYFOVRE sales, in a deal valued at roughly $5.6 billion upfront.
- Who is Apellis Pharmaceuticals' biggest competitor?
- Astellas Pharma, via its 2023 $5.9 billion Iveric Bio acquisition, markets Izervay, the second FDA-approved geographic atrophy treatment competing directly with Apellis's SYFOVRE; a 2024 network meta-analysis suggested Izervay may outperform on some measures.
- Could AI replace what Apellis Pharmaceuticals does?
- No. Apellis's value rests on FDA-approved first-in-class drug labels (SYFOVRE, EMPAVELI), proprietary Phase 3 trial data, and physician-administered injections, none of which AI can substitute for; no Apellis-specific AI deployment was found as of its February 2026 earnings call.
- Is SYFOVRE facing lawsuits?
- Yes. As of July 10, 2026, an active securities fraud class action alleges Apellis misled investors about SYFOVRE trial design and retinal vasculitis risk, and separate product-liability suits over vision loss and retinal vasculitis have been filed since at least February 2025.
Timeline
- 2026-05-14Biogen completes acquisition; Apellis becomes wholly owned subsidiary, APLS delisted from Nasdaq
- 2026-05-13Tender offer expires; about 82.4% of Apellis shares tendered to Biogen
- 2026-05-07Q1 2026 results: revenue $268.3M (+61% YoY), first net income of $18.7M
- 2026-03-31Biogen and Apellis announce merger agreement: $41.00/share cash plus CVR up to $4/share
- 2026-02-24FY2025 results: total revenue $1.004B, up 28.5% YoY; SYFOVRE ~60% US GA share
- 2025-07EMPAVELI approved for C3G and primary IC-MPGN, expanding beyond PNH
- 2023-12Novartis's Fabhalta (iptacopan) approved for PNH, competing with EMPAVELI
- 2023-02SYFOVRE (pegcetacoplan) approved by FDA as first-in-class geographic atrophy treatment
- 2017-11-09Apellis IPOs on Nasdaq under ticker APLS
Revision history
24 July 2026
First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Biogen Completes Acquisition of Apellis Pharmaceuticals (2026-05-14)
- Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease (2026-03-31)
- Apellis Stock Disappears From Nasdaq as Biogen $41 Billion Buyout Faces Final Hurdle (2026-05-21)
- Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results (2026-02-24)
- Apellis Pharmaceuticals Revenue 2016-2026 (2026-03-30)
- Apellis Q1 FY26 swings to net income of $18.66 million; revenue rises 61% to $268.3 million (2026-05-07)
- Apellis (APLS) Q4 2025 Earnings Call Transcript (2026-02-24)
- Apellis Pharmaceuticals (APLS) Number of Employees (2026-05-14)
- Apellis Pharmaceuticals - Headcount, Funding & Open Jobs (2026-06-23)
- 10-K (2026-12-31)
- The geographic atrophy treatment battle (2026-02-16)
- Efficacy and safety of complement inhibitors (2024-11-12)